Structure Therapeutics Inc. Sponsored ADR $GPCR Stock Holdings Lowered by Flax Pond Capital LLC

Flax Pond Capital LLC lessened its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 26.1% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 36,000 shares of the company’s stock after selling 12,721 shares during the period. Structure Therapeutics makes up 1.4% of Flax Pond Capital LLC’s portfolio, making the stock its 26th biggest position. Flax Pond Capital LLC’s holdings in Structure Therapeutics were worth $1,735,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Structure Therapeutics by 18.5% in the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after purchasing an additional 8,444 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Structure Therapeutics by 7.6% during the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after buying an additional 30,162 shares during the last quarter. Marshall Wace LLP boosted its position in shares of Structure Therapeutics by 474.9% during the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after buying an additional 145,434 shares during the period. Jump Financial LLC boosted its position in shares of Structure Therapeutics by 105.9% during the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after buying an additional 32,524 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Structure Therapeutics during the second quarter worth approximately $3,480,000. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Up 4.5%

GPCR stock opened at $49.47 on Friday. The firm’s 50-day moving average is $46.33 and its two-hundred day moving average is $55.30. The company has a market capitalization of $3.52 billion, a price-to-earnings ratio of -56.86 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 52 week low of $15.80 and a 52 week high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.04. On average, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently commented on GPCR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Friday, July 17th. Wall Street Zen lowered Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Finally, HC Wainwright decreased their price target on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $110.55.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.